Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NYSEAMERICAN:CVM NASDAQ:ELUT OTCMKTS:ETST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.90-7.0%$5.65$7.96▼$24.15$24.71M0.6315,685 shs65,416 shsCVMCel-Sci$1.49+0.7%$2.81$0.89▼$13.48$12.57M0.54831,899 shs177,759 shsELUTElutia$1.04-1.9%$1.10$0.50▼$2.64$45.35M0.8142,375 shs48,455 shsETSTEarth Science Tech$0.17-1.7%$0.14$0.00▼$0.24$51.44M2.38103,694 shs5,305 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir0.00%+7.11%-3.48%-49.42%+81.72%CVMCel-Sci-3.90%+4.23%-35.09%-58.31%-29.52%ELUTElutia-8.62%-8.62%+4.95%-13.11%-41.11%ETSTEarth Science Tech-0.28%+7.27%+26.25%+60.91%+26.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.90-7.0%$5.65$7.96▼$24.15$24.71M0.6315,685 shs65,416 shsCVMCel-Sci$1.49+0.7%$2.81$0.89▼$13.48$12.57M0.54831,899 shs177,759 shsELUTElutia$1.04-1.9%$1.10$0.50▼$2.64$45.35M0.8142,375 shs48,455 shsETSTEarth Science Tech$0.17-1.7%$0.14$0.00▼$0.24$51.44M2.38103,694 shs5,305 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir0.00%+7.11%-3.48%-49.42%+81.72%CVMCel-Sci-3.90%+4.23%-35.09%-58.31%-29.52%ELUTElutia-8.62%-8.62%+4.95%-13.11%-41.11%ETSTEarth Science Tech-0.28%+7.27%+26.25%+60.91%+26.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/ACVMCel-Sci 0.00N/AN/AN/AELUTElutia 2.50Moderate Buy$6.00476.92% UpsideETSTEarth Science Tech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CVM, ETST, ELUT, and ALVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ACVMCel-SciN/AN/AN/AN/A$2.32 per shareN/AELUTElutia$12.29M3.62N/AN/A$0.65 per share1.60ETSTEarth Science Tech$33.12M1.53$0.01 per share15.30$0.01 per share17.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/ACVMCel-Sci-$25.41M-$9.77N/AN/AN/AN/A-274.86%-126.47%N/AELUTElutia$53.38M$0.86N/AN/AN/A312.09%N/A-53.97%8/14/2026 (Estimated)ETSTEarth Science Tech$3.25MN/AN/A5.80N/A10.02%73.51%44.22%6/25/2026 (Estimated)Latest CVM, ETST, ELUT, and ALVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/25/2026N/AETSTEarth Science Tech$0.01N/AN/AN/A$8.91 millionN/A5/15/2026Q2 2026CVMCel-SciN/A-$0.67N/A-$0.67N/AN/A5/14/2026Q1 2026ELUTElutia-$0.15-$0.17-$0.02-$0.17$3.00 million$3.11 million3/11/2026Q4 2025ELUTElutia-$0.14-$0.14N/A$1.48$3.30 million$3.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ACVMCel-SciN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78CVMCel-Sci0.640.600.54ELUTElutiaN/A2.051.94ETSTEarth Science TechN/A1.340.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%CVMCel-Sci12.08%ELUTElutia74.03%ETSTEarth Science TechN/AInsider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%CVMCel-Sci14.06%ELUTElutia27.60%ETSTEarth Science Tech24.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionNo DataCVMCel-Sci438.49 million7.30 millionOptionableELUTElutia18042.78 million30.98 millionNot OptionableETSTEarth Science Tech3290.61 million218.25 millionNot OptionableCVM, ETST, ELUT, and ALVR HeadlinesRecent News About These CompaniesEarth Science Tech, Inc. (ETST) Launches MyOnlineConsultation.com, Finalizing a Fully Vertically Integrated Telehealth and Pharmacy EcosystemMarch 24, 2026 | globenewswire.comETST: F2Q26 earnings review – increasing visibility into accelerating growth and stronger financial performanceFebruary 18, 2026 | msn.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Giorgio R. Saumat, CEO of Earth Science Tech Inc.February 17, 2026 | markets.businessinsider.comEarth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of ...February 17, 2026 | manilatimes.netMEarth Science Tech, Inc. (ETST) Reports Third Fiscal Quarter 2026 ResultsFebruary 17, 2026 | markets.businessinsider.comEarth Science Tech, Inc. Announces Initiatives to Advance Public Company Strategy; Expects Approximately $1.4 Million in Annualized Savings and Fiscal 2026 Net Income Growth of More Than 40%, from $3.3 Million to $4.7 MillionFebruary 17, 2026 | globenewswire.comEarth Science Tech, Inc. (ETST) Upgrades Audit Capabilities, Engages Semple, Marchal & Cooper, LLP as Independent PCAOB Auditor to Support Continued ExpansionFebruary 17, 2026 | globenewswire.comEarth Science Tech, Inc. (ETST), to Report Financial Results for Fiscal Third Quarter on February 17, 2026February 9, 2026 | globenewswire.comJapan hauls rare earth-rich mud from deep sea in bold test missionFebruary 4, 2026 | msn.comIBN Initiates Coverage of Earth Science Tech Inc.January 23, 2026 | globenewswire.comEarth Science Tech, Inc. (ETST) Engages Hayden IR, Expanding Investor Relations Efforts to Support its Investor Outreach and CommunicationsJanuary 6, 2026 | markets.businessinsider.comEarth Science Tech, Inc. Receives FINRA Clearance on Form 211 to Initiate QuotationsDecember 15, 2025 | manilatimes.netMEarth Science Tech Reports Strong Q2 Financial GrowthNovember 12, 2025 | tipranks.comEarth Science Tech, Inc. Reports Strong Q2 Fiscal 2025 ResultsNovember 12, 2025 | globenewswire.comSimulating Habitable Worlds Observatory's ability to characterize Earth-sized exoplanetsSeptember 30, 2025 | msn.comNASA’s final Psyche laser message reaches Earth after 218-million-mile journeySeptember 30, 2025 | msn.comEarth Just Received Final NASA Laser Message From 218 Million Miles AwaySeptember 30, 2025 | msn.comEarth Science Tech, Inc. Boosts Share Repurchase Program to $10 Million and Extends Authorization Through 2027August 20, 2025 | globenewswire.comEarth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common StockAugust 19, 2025 | globenewswire.comEarth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8. ...August 8, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVM, ETST, ELUT, and ALVR Company DescriptionsAlloVir NASDAQ:ALVR$4.90 -0.37 (-7.02%) As of 06/1/2026AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Cel-Sci NYSEAMERICAN:CVM$1.49 +0.01 (+0.68%) Closing price 04:10 PM EasternExtended Trading$1.49 +0.00 (+0.27%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Elutia NASDAQ:ELUT$1.04 -0.02 (-1.89%) Closing price 04:00 PM EasternExtended Trading$1.04 +0.00 (+0.48%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Earth Science Tech OTCMKTS:ETST$0.17 0.00 (-1.69%) As of 12:50 PM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
